Form 8-K Intra-Cellular Therapies For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 8c
August 4, 2016 8:53 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $223.45 thousand versus the consensus estimate of $20 thousand.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More